Molecular recognition of gangliosides and their potential for cancer immunotherapies

Frontiers in Immunology

Volumn 5, Issue JUL, 2014, Pages

  Krengel, Ute ^a   Bousquet, Paula A ^a  

^a UNIVERSITY OF OSLO   (Norway)

Author keywords

Biological membranes; Cancer immunotherapy; Cell signaling; Gangliosides; Glycosphingolipids; Protein carbohydrate interactions; Sialic acid; Tumor associated antigens

Indexed keywords

EID: 84905647126     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2014.00325     Document Type: Review

References (154)

1. Svennerholm L. Chromatographic separation of human brain gangliosides. J Neurochem (1963) 10:613-23. doi: 10.1111/j.1471-4159.1963.tb08933.x
2. Nomenclature Committee, Consortium for Functional Glycomics. Symbol and Text Nomenclature for Representation of Glycan Structure. (2014). Available from: http://www.functionalglycomics.org/static/consortium/Nomenclature.shtml.
3. Schwarz A, Futerman AH. The localization of gangliosides in neurons of the central nervous system: the use of anti-ganglioside antibodies. Biochim Biophys Acta (1996) 1286(3):247-67. doi:10.1016/S0304-4157(96)00011-1
4. Yu RK, Yanagisawa M, Ariga T. Glycosphingolipid structures. In: Kamerling JP, editor. Comprehensive Glycoscience (Vol. 1), Oxford: Elsevier (2007). p. 73-122.
5. Yu RK, Tsai Y-T, Ariga T, Yanagisawa M. Structures, biosynthesis, and functions of gangliosides - an overview. J Oleo Sci (2011) 60(10):537-44. doi:10.5650/jos.60.537
6. Futerman AH, Hannun YA. The complex life of simple sphingolipids. EMBO Rep (2004) 5(8):777-82. doi:10.1038/sj.embor.7400208
7. Shevchenko A, Simons K. Lipidomics: coming to grips with lipid diversity. Nat Rev Mol Cell Biol (2010) 11(8):593-8. doi:10.1038/nrm2934
8. Simons K, Sampaio JL. Membrane organization and lipid rafts. Cold Spring Harb Perspect Biol (2011) 3(10):a004697. doi:10.1101/cshperspect.a004697
9. Lopez PHH, Schnaar RL. Gangliosides in cell recognition and membrane protein regulation. Curr Opin Struct Biol (2009) 19(5):549-57. doi:10.1016/j.sbi.2009.06.001
10. Sonnino S, Mauri L, Chigorno V, Prinetti A. Gangliosides as components of lipid membrane domains. Glycobiology (2007) 17(1):1R-13R. doi:10.1093/glycob/cwl052
11. Hanada K, Kumagai K, Yasuda S, Miura Y, Kawano M, Fukasawa M, et al. Molecular machinery for non-vesicular trafficking of ceramide. Nature (2003) 426(6968):803-9. doi:10.1038/nature02188
12. Merrill AH Jr. De novo sphingolipid biosynthesis: a necessary, but dangerous, pathway. J Biol Chem (2002) 277(29):25843-6. doi:10.1074/jbc.R200009200
13. Kolter T, Proia RL, Sandhoff K. Combinatorial ganglioside biosynthesis. J Biol Chem (2002) 277(29):25859-62. doi:10.1074/jbc.R200001200
14. Zeng G, Yu RK. Cloning and transcriptional regulation of genes responsible for synthesis of gangliosides. Curr Drug Targets (2008) 9(4):317-24. doi:10.2174/138945008783954925
15. Maccioni HJF. Glycosylation of glycolipids in the Golgi complex. J Neurochem (2007) 103(Suppl 1):81-90. doi:10.1111/j.1471-4159.2007.04717.x
16. Tettamanti G. Ganglioside/glycosphingolipid turnover: new concepts. Glycoconj J (2004) 20(5):301-17. doi:10.1023/B:GLYC.0000033627.02765.cc
17. Sandhoff K, Kolter T. Biosynthesis and degradation of mammalian glycosphingolipids. Philos Trans R Soc Lond B Biol Sci (2003) 358(1433):847-61. doi:10.1098/rstb.2003.1265
18. Saito M, Sugiyama K. Characterization of nuclear gangliosides in rat brain: concentration, composition, and developmental changes. Arch Biochem Biophys (2002) 398(2):153-9. doi:10.1006/abbi.2001.2725
19. Ledeen RW, Wu G. Nuclear lipids: key signaling effectors in the nervous system and other tissues. J Lipid Res (2004) 45(1):1-8. doi:10.1194/jlr.R300015-JLR200
20. Yamashita T, Wada R, Sasaki T, Deng C, Bierfreund U, Sandhoff K, et al. A vital role for glycosphingolipid synthesis during development and differentiation. Proc Natl Acad Sci U S A (1999) 96(16):9142-7. doi:10.1073/pnas.96.16.9142
21. Yamashita T, Hashiramoto A, Haluzik M, Mizukami H, Beck S, Norton A, et al. Enhanced insulin sensitivity in mice lacking ganglioside GM3. Proc Natl Acad Sci U S A (2003) 100(6):3445-9. doi:10.1073/pnas.0635898100
22. Takamiya K, Yamamoto A, Furukawa K, Yamashiro S, Shin M, Okada M, et al. Mice with disrupted GM2/GD2 synthase gene lack complex gangliosides but exhibit only subtle defects in their nervous system. Proc Natl Acad Sci U S A (1996) 93(20):10662-7. doi:10.1073/pnas.93.20.10662
23. Simons K, Toomre D. Lipid rafts and signal transduction. Nat Rev Mol Cell Biol (2000) 1(1):31-9. doi:10.1038/35036052
24. Simons K, Ikonen E. Functional rafts in cell membranes. Nature (1997) 387(6633):569-72. doi:10.1038/42408
25. Hakomori SI., Igarashi Y. Functional role of glycosphingolipids in cell recognition and signaling. J Biochem (1995) 118(6):1091-103.
26. Bremer EG, Schlessinger J, Hakomori SI. Ganglioside-mediated modulation of cell growth. Specific effects of GM3 on tyrosine phosphorylation of the epidermal growth factor receptor. J Biol Chem (1986) 261(5):2434-40.
27. Imberty A, Varrot A. Microbial recognition of human cell surface glycoconjugates. Curr Opin Struct Biol (2008) 18(5):567-76. doi:10.1016/j.sbi.2008.08.001
28. Lehmann F, Tiralongo E, Tiralongo J. Sialic acid-specific lectins: occurrence, specificity and function. Cell Mol Life Sci (2006) 63(12):1331-54. doi:10.1007/s00018-005-5589-y
29. Schauer R, Srinivasan GV, Wipfler D, Kniep B, Schwartz-Albiez R. O-acetylated sialic acids and their role in immune defense. In: Wu AM, editor. The Molecular Immunology of Complex Carbohydrates-3. Advances in Experimental Medicine and Biology (Vol. 705). New York: Springer (2011). p. 525-48. doi:10.1007/978-1-4419-7877-6_28
30. Suzuki Y, Nagao Y, Kato H, Matsumoto M, Nerome K, Nakajima K, et al. Human influenza A virus hemagglutinin distinguishes sialyloligosaccharides in membrane-associated gangliosides as its receptor which mediates the adsorption and fusion processes of virus infection. Specificity for oligosaccharides and sialic acids and the sequence to which sialic acid is attached. J Biol Chem (1986) 261(36):17057-61.
31. Neu U, Woellner K, Gauglitz G, Stehle T. Structural basis of GM1 ganglioside recognition by simian virus 40. Proc Natl Acad Sci U S A (2008) 105(13):5219-24. doi:10.1073/pnas.0710301105
32. Erickson KD, Garcea RL, Tsai B. Ganglioside GT1b is a putative host cell receptor for the Merkel cell polyomavirus. J Virol (2009) 83(19):10275-9. doi:10.1128/JVI.00949-09
33. Neu U, Maginnis MS, Palma AS, Ströh LJ, Nelson CDS, Feizi T, et al. Structure-function analysis of the human JC polyomavirus establishes the LSTc pentasaccharide as a functional receptor motif. Cell Host Microbe (2010) 8(4):309-19. doi:10.1016/j.chom.2010.09.004
34. Merritt EA, Sarfaty S, van den Akker F, L'Hoir C, Martial JA, Hol WGJ. Crystal structure of cholera toxin B-pentamer bound to receptor GM1 pentasaccharide. Prot Sci (1994) 3(2):166-75. doi:10.1002/pro.5560030202
35. Mahdavi J, Sondén B, Hurtig M, Olfat FO, Forsberg L, Roche N, et al. Helicobacter pylori SabA adhesin in persistent infection and chronic inflammation. Science (2002) 297(5581):573-8. doi:10.1126/science.1069076
36. Roche N, Ångström J, Hurtig M, Larsson T, Borén T, Teneberg S. Helicobacter pylori and complex gangliosides. Infect Immun (2004) 72(3):1519-29. doi:10.1128/IAI.72.3.1519-1529.2004
37. Drickamer K. Making a fitting choice: common aspects of sugar-binding sites in plant and animal lectins. Structure (1997) 5(4):465-8. doi:10.1016/S0969-2126(97)00202-5
38. Gabius H-J, André S, Jiménez-Barbero J, Romero A, Solís D. From lectin structure to functional glycomics: principles of the sugar code. Trends Biochem Sci (2011) 36(6):298-313. doi:10.1016/j.tibs.2011.01.005
39. del Carmen Fernández-Alonso M, Cañada FJ, Jiménez-Barbero J, Cuevas G. Molecular recognition of saccharides by proteins. Insights on the origin of the carbohydrate-aromatic interactions. J Am Chem Soc (2005) 127(20):7379-86. doi:10.1021/ja051020+
40. Stenmark P, Dupuy J, Imamura A, Kiso M, Stevens RC. Crystal structure of botulinum neurotoxin type A in complex with the cell surface co-receptor GT1b - insight into the toxin-neuron interaction. PLoS Pathog (2008) 4(8):e1000129. doi:10.1371/journal.ppat.1000129
41. Lis H, Sharon N. Lectins: carbohydrate-specific proteins that mediate cellular recognition. Chem Rev (1998) 98(2):637-74. doi:10.1021/cr940413g
42. Baker HM, Basu I, Chung MC, Caradoc-Davies T, Fraser JD, Baker EN. Crystal structures of the staphylococcal toxin SSL5 in complex with sialyl Lewis X reveal a conserved binding site that shares common features with viral and bacterial sialic acid binding proteins. J Mol Biol (2007) 374(5):1298-308. doi:10.1016/j.jmb.2007.09.091
43. Lauer S, Goldstein B, Nolan RL, Nolan JP. Analysis of cholera toxin-ganglioside interactions by flow cytometry. Biochemistry (2002) 41(6):1742-51. doi:10.1021/bi0112816
44. Siebert H-C, André S, Lu S-Y, Frank M, Kaltner H, van Kuik JA, et al. Unique conformer selection of human growth-regulatory lectin galectin-1 for ganglioside GM1 versus bacterial toxins. Biochemistry (2003) 42(50):14762-73. doi:10.1021/bi035477c
45. Gabius H-J, Wu AM. The emerging functionality of endogenous lectins: a primer to the concept and a case study on galectins including medical implications. Chang Gung Med J (2006) 29(1):37-62.
46. Vattulainen I, Rog T. Lipid simulations: a perspective on lipids in action. Cold Spring Harb Perspect Biol (2011) 3(4). doi:10.1101/cshperspect.a004655
47. DeMarco ML, Woods RJ. Atomic-resolution conformational analysis of the GM3 ganglioside in a lipid bilayer and its implications for ganglioside-protein recognition at membrane surfaces. Glycobiology (2009) 19(4):344-55. doi:10.1093/glycob/cwn137
48. May AP, Robinson RC, Vinson M, Crocker PR, Jones EY. Crystal structure of the N-terminal domain of sialoadhesin in complex with 3' sialyllactose at 1.85 Å resolution. Mol Cell (1998) 1(5):719-28. doi:10.1016/S1097-2765(00)80071-4
49. Wright CS. 2.2 Å resolution structure analysis of two refined N-acetylneuraminyl-lactose - wheat germ agglutinin isolectin complexes. J Mol Biol (1990) 215(4):635-51. doi:10.1016/S0022-2836(05)80174-3
50. Frolov VA, Shnyrova AV, Zimmerberg J. Lipid polymorphisms and membrane shape. Cold Spring Harb Perspect Biol (2011) 3(11):a004747. doi:10.1101/cshperspect.a004747
51. Coskun ü, Simons K. Membrane rafting: from apical sorting to phase segregation. FEBS Lett (2010) 584(9):1685-93. doi:10.1016/j.febslet.2009.12.043
52. Taniguchi M, Wakabayashi S. Shared antigenic determinant expressed on various mammalian melanoma cells. Gann (1984) 75(5):418-26.
53. Hirabayashi Y, Hamaoka A, Matsumoto M, Matsubara T, Tagawa M, Wakabayashi S, et al. Syngeneic monoclonal antibody against melanoma antigen with interspecies cross-reactivity recognizes GM3, a prominent ganglioside of B16 melanoma. J Biol Chem (1985) 260(24):13328-33.
54. Nores GA, Dohi T, Taniguchi M, Hakomori SI. Density-dependent recognition of cell surface GM3 by a certain anti-melanoma antibody, and GM3 lactone as a possible immunogen: requirements for tumor-associated antigen and immunogen. J Immunol (1987) 139(9):3171-6.
55. Hakomori SI., Nudelman E, Levery S, Solter D, Knowles BB. The hapten structure of a developmentally regulated glycolipid antigen (SSEA-1) isolated from human erythrocytes and adenocarcinoma: a preliminary note. Biochem Biophys Res Commun (1981) 100(4):1578-86. doi:10.1016/0006-291X(81)90699-9
56. Yahi N, Aulas A, Fantini J. How cholesterol constrains glycolipid conformation for optimal recognition of Alzheimer's ß amyloid peptide (Aß1-40). PLoS One (2010) 5(2):e9079. doi:10.1371/journal.pone.0009079
57. Lingwood D, Binnington B, Róg T, Vattulainen I, Grzybek M, Coskun ü, et al. Cholesterol modulates glycolipid conformation and receptor activity. Nat Chem Biol (2011) 7(5):260-2. doi:10.1038/nchembio.551
58. Nyholm P-G, Pascher I, Sundell S. The effect of hydrogen bonds on the conformation of glycosphingolipids. Methylated and unmethylated cerebroside studied by X-ray single crystal analysis and model calculations. Chem Phys Lipids (1990) 52(1):1-10. doi:10.1016/0009-3084(90)90002-9
59. Sandvig K, Bergan J, Kavaliauskiene S, Skotland T. Lipid requirements for entry of protein toxins into cells. Prog Lipid Res (2014) 54C:1-13. doi:10.1016/j.plipres.2014.01.001
60. Pascher I. Molecular arrangements in sphingolipids. Conformation and hydrogen bonding of ceramide and their implication on membrane stability and permeability. Biochim Biophys Acta (1976) 455(2):433-51. doi:10.1016/0005-2736(76)90316-3
61. Walker F, Abramowitz L, Benabderrahmane D, Duval X, Descatoire V, Hénin D, et al. Growth factor receptor expression in anal squamous lesions: modifications associated with oncogenic human papillomavirus and human immunodeficiency virus. Hum Pathol (2009) 40(11):1517-27. doi:10.1016/j.humpath.2009.05.010
62. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med (2004) 350(21):2129-39. doi:10.1056/NEJMoa040938
63. Kuan C-T, Wikstrand CJ, Bigner DD. EGF mutant receptor vIII as a molecular target in cancer therapy. Endocr Relat Cancer (2001) 8(2):83-96. doi:10.1677/erc.0.0080083
64. Ferrara N, Kerbel RS. Angiogenesis as a therapeutic target. Nature (2005) 438(7070):967-74. doi:10.1038/nature04483
65. Kawashima N, Yoon S-J, Itoh K, Nakayama K-i. Tyrosine kinase activity of epidermal growth factor receptor is regulated by GM3 binding through carbohydrate to carbohydrate interactions. J Biol Chem (2009) 284(10):6147-55. doi:10.1074/jbc.M808171200
66. Coskun ü, Grzybek M, Drechsel D, Simons K. Regulation of human EGF receptor by lipids. Proc Natl Acad Sci U S A (2011) 108(22):9044-8. doi:10.1073/pnas.1105666108
67. Yoon S-J, Nakayama K-i, Hikita T, Handa K, Hakomori SI. Epidermal growth factor receptor tyrosine kinase is modulated by GM3 interaction with N-linked GlcNAc termini of the receptor. Proc Natl Acad Sci U S A (2006) 103(50):18987-91. doi:10.1073/pnas.0609281103
68. Mirkin BL, Clark SH, Zhang C. Inhibition of human neuroblastoma cell proliferation and EGF receptor phosphorylation by gangliosides GM1, GM3, GD1A and GT1B. Cell Prolif (2002) 35(2):105-15. doi:10.1046/j.1365-2184.2002.00228.x
69. Hofman EG, Bader AN, Gerritsen HC, van Bergenen Henegouwen PMP. EGF induces rapid reorganization of plasma membrane microdomains. Commun Integr Biol (2009) 2(3):213-4. doi:10.4161/cib.2.3.7877
70. Miljan EA, Meuillet EJ, Mania-Farnell B, George D, Yamamoto H, Simon H-G, et al. Interaction of the extracellular domain of the epidermal growth factor receptor with gangliosides. J Biol Chem (2002) 277(12):10108-13. doi:10.1074/jbc.M111669200
71. Zurita AR, Crespo PM, Koritschoner NP, Daniotti JL. Membrane distribution of epidermal growth factor receptors in cells expressing different gangliosides. Eur J Biochem (2004) 271(12):2428-37. doi:10.1111/j.1432-1033.2004.04165.x
72. Wang J, Yu RK. Interaction of ganglioside GD3 with an EGF receptor sustains the self-renewal ability of mouse neural stem cells in vitro. Proc Natl Acad Sci U S A (2013) 110(47):19137-42. doi:10.1073/pnas.1307224110
73. Liu Y, Li R, Ladisch S. Exogenous ganglioside GD1a enhances epidermal growth factor receptor binding and dimerization. J Biol Chem (2004) 279(35):36481-9. doi:10.1074/jbc.M402880200
74. Chung T-W, Kim S-J, Choi H-J, Kim K-J, Kim M-J, Kim S-H, et al. Ganglioside GM3 inhibits VEGF/VEGFR-2-mediated angiogenesis: direct interaction of GM3 with VEGFR-2. Glycobiology (2009) 19(3):229-39. doi:10.1093/glycob/cwn114
75. Mukherjee P, Faber AC, Shelton LM, Baek RC, Chiles TC, Seyfried TN. Thematic Review Series: Sphingolipids. Ganglioside GM3 suppresses the proangiogenic effects of vascular endothelial growth factor and ganglioside GD1a. J Lipid Res (2008) 49(5):929-38.
76. Liu Y, McCarthy J, Ladisch S. Membrane ganglioside enrichment lowers the threshold for vascular endothelial cell angiogenic signaling. Cancer Res (2006) 66(21):10408-14. doi:10.1158/0008-5472.CAN-06-1572
77. Zeng G, Gao L, Birklé S, Yu RK. Suppression of ganglioside GD3 expression in a rat F-11 tumor cell line reduces tumor growth, angiogenesis, and vascular endothelial growth factor production. Cancer Res (2000) 60(23):6670-6.
78. Downward J, Parker P, Waterfield MD. Autophosphorylation sites on the epidermal growth factor receptor. Nature (1984) 311(5985):483-5. doi:10.1038/311483a0
79. Oda K, Matsuoka Y, Funahashi A, Kitano H. A comprehensive pathway map of epidermal growth factor receptor signaling. Mol Syst Biol (2005) 1(1):1-17. doi:10.1038/msb4100014
80. Endres NF, Engel K, Das R, Kovacs E, Kuriyan J. Regulation of the catalytic activity of the EGF receptor. Curr Opin Struct Biol (2011) 21(6):777-84. doi:10.1016/j.sbi.2011.07.007
81. Kabayama K, Sato T, Saito K, Loberto N, Prinetti A, Sonnino S, et al. Dissociation of the insulin receptor and caveolin-1 complex by ganglioside GM3 in the state of insulin resistance. Proc Natl Acad Sci U S A (2007) 104(34):13678-83. doi:10.1073/pnas.0703650104
82. Nojiri H, Stroud M, Hakomori SI. A specific type of ganglioside as a modulator of insulin-dependent cell growth and insulin receptor tyrosine kinase activity. Possible association of ganglioside-induced inhibition of insulin receptor function and monocytic differentiation induction in HL-60 cells. J Biol Chem (1991) 266(7):4531-7.
83. Wang X-Q, Sun P, Paller AS. Ganglioside GM3 blocks the activation of epidermal growth factor receptor induced by integrin at specific tyrosine sites. J Biol Chem (2003) 278(49):48770-8. doi:10.1074/jbc.M308818200
84. Yoon S-J, Nakayama K-i, Takahashi N, Yagi H, Utkina N, Wang HY, et al. Interaction of N-linked glycans, having multivalent GlcNAc termini, with GM3 ganglioside. Glycoconj J (2006) 23(9):639-49. doi:10.1007/s10719-006-9001-4
85. Handa K, Hakomori SI. Carbohydrate to carbohydrate interaction in development process and cancer progression. Glycoconj J (2012) 29(8-9):627-37. doi:10.1007/s10719-012-9380-7
86. Arkhipov A, Shan Y, Das R, Endres NF, Eastwood MP, Wemmer DE, et al. Architecture and membrane interactions of the EGF receptor. Cell (2013) 152(3):557-69. doi:10.1016/j.cell.2012.12.030
87. Sezgin E, Levental I, Grzybek M, Schwarzmann G, Mueller V, Honigmann A, et al. Partitioning, diffusion, and ligand binding of raft lipid analogs in model and cellular plasma membranes. Biochim Biophys Acta (2012) 1818(7):1777-84. doi:10.1016/j.bbamem.2012.03.007
88. Hakomori SI. Tumor malignancy defined by aberrant glycosylation and sphingo(glyco)lipid metabolism. Cancer Res (1996) 56(23):5309-18.
89. Ravindranath MH, Tsuchida T, Morton DL, Irie RF. Ganglioside GM3:GD3 ratio as an index for the management of melanoma. Cancer (1991) 67(12):3029-35. doi:10.1002/1097-0142(19910615)67:123029::AID-CNCR28206712173.0.CO;2-8
90. Carubia JM, Yu RK, Macala LJ, Kirkwood JM, Varga JM. Gangliosides of normal and neoplastic human melanocytes. Biochem Biophys Res Commun (1984) 120(2):500-4. doi:10.1016/0006-291X(84)91282-8
91. Merzak A, Koochekpour S, Pilkington GJ. Cell surface gangliosides are involved in the control of human glioma cell invasion in vitro. Neurosci Lett (1994) 177(1-2):44-6. doi:10.1016/0304-3940(94)90040-X
92. Nicoll G, Avril T, Lock K, Furukawa K, Bovin N, Crocker PR. Ganglioside GD3 expression on target cells can modulate NK cell cytotoxicity via siglec-7-dependent and -independent mechanisms. Eur J Immunol (2003) 33(6):1642-8. doi:10.1002/eji.200323693
93. Ando I, Hoon DS, Suzuki Y, Saxton RE, Golub SH, Irie RF. Ganglioside GM2 on the K562 cell line is recognized as a target structure by human natural killer cells. Int J Cancer (1987) 40(1):12-7. doi:10.1002/ijc.2910400104
94. Biswas K, Richmond A, Rayman P, Biswas S, Thornton M, Sa G, et al. GM2 expression in renal cell carcinoma: potential role in tumor-induced T-cell dysfunction. Cancer Res (2006) 66(13):6816-25. doi:10.1158/0008-5472.CAN-06-0250
95. Grayson G, Ladisch S. Immunosuppression by human gangliosides. II. Carbohydrate structure and inhibition of human NK activity. Cell Immunol (1992) 139(1):18-29. doi:10.1016/0008-8749(92)90096-8
96. Morton DL, Barth A. Vaccine therapy for malignant melanoma. CA Cancer J Clin (1996) 46(4):225-44. doi:10.3322/canjclin.46.4.225
97. Pukel CS, Lloyd KO, Travassos LR, Dippold WG, Oettgen HF, Old LJ. GD3, a prominent ganglioside of human melanoma. Detection and characterisation by mouse monoclonal antibody. J Exp Med (1982) 155(4):1133-47. doi:10.1084/jem.155.4.1133
98. van Cruijsen H, Ruiz MG, van der Valk P, de Gruijl TD, Giaccone G. Tissue micro array analysis of ganglioside N-glycolyl GM3 expression and signal transducer and activator of transcription (STAT)-3 activation in relation to dendritic cell infiltration and microvessel density in non-small cell lung cancer. BMC Cancer (2009) 9:180. doi:10.1186/1471-2407-9-180
99. Marquina G, Waki H, Fernandez LE, Kon K, Carr A, Valiente O, et al. Gangliosides expressed in human breast cancer. Cancer Res (1996) 56(22):5165-71.
100. Kudo D, Rayman P, Horton C, Cathcart MK, Bukowski RM, Thornton M, et al. Gangliosides expressed by the renal cell carcinoma cell line SK-RC-45 are involved in tumor-induced apoptosis of T cells. Cancer Res (2003) 63(7):1676-83.
101. Higashi H, Hirabayashi Y, Fukui Y, Naiki M, Matsumoto M, Ueda S, et al. Characterization of N-glycolylneuraminic acid-containing gangliosides as tumor-associated Hanganutziu-Deicher antigen in human colon cancer. Cancer Res (1985) 45(8):3796-802.
102. Hirabayashi Y, Higashi H, Kato S, Taniguchi M, Matsumoto M. Occurrence of tumor-associated ganglioside antigens with Hanganutziu-Deicher antigenic activity on human melanomas. Jpn J Cancer Res (1987) 78(6):614-20.
103. Scursoni AM, Galluzzo L, Camarero S, Lopez J, Lubieniecki F, Sampor C, et al. Detection of N-Glycolyl GM3 ganglioside in neuroectodermal tumors by immunohistochemistry: an attractive vaccine target for aggressive pediatric cancer. Clin Dev Immunol (2011) 2011:245181. doi:10.1155/2011/245181
104. Scursoni AM, Galluzzo L, Camarero S, Pozzo N, Gabri MR, de Acosta CM, et al. Detection and characterization of N-glycolyated gangliosides in Wilms tumor by immunohistochemistry. Pediatr Dev Pathol (2009) 13(1):18-23. doi:10.2350/08-10-0544.1
105. Hettmer S, Ladisch S, Kaucic K. Low complex ganglioside expression characterizes human neuroblastoma cell lines. Cancer Lett (2005) 225(1):141-9. doi:10.1016/j.canlet.2004.11.036
106. Brezicka F-T, Olling S, Nilsson O, Bergh J, Holmgren J, Sörenson S, et al. Immunohistological detection of fucosyl-GM1 ganglioside in human lung cancer and normal tissues with monoclonal antibodies. Cancer Res (1989) 49(5):1300-5.
107. Okada M, Furukawa K, Yamashiro S, Yamada Y, Haraguchi M, Horibe K, et al. High expression of ganglioside a-2,8-Sialyltransferase (GD3 Synthase) gene in adult T-cell leukemia cells unrelated to the gene expression of human T-lymphotropic virus type I. Cancer Res (1996) 56(12):2844-8.
108. Cheung N-K, Saarinen UM, Neely JE, Landmeier B, Donovan D, Coccia PF. Monoclonal antibodies to a glycolipid antigen on human neuroblastoma cells. Cancer Res (1985) 45(6):2642-9.
109. Mujoo K, Cheresh DA, Yang HM, Reisfeld RA. Disialoganglioside GD2 on human neuroblastoma cells: target antigen for monoclonal antibody-mediated cytolysis and suppression of tumor growth. Cancer Res (1987) 47(4):1098-104.
110. Steenackers A, Vanbeselaere J, Cazet A, Bobowski M, Rombouts Y, Colomb F, et al. Accumulation of unusual gangliosides GQ3 and GP3 in breast cancer cells expressing the GD3 synthase. Molecules (2012) 17(8):9559-72. doi:10.3390/molecules17089559
111. Bobowski M, Vincent A, Steenackers A, Colomb F, Van Seuningen I, Julien S, et al. Estradiol represses the GD3 synthase gene ST8SIA1 expression in human breast cancer cells by preventing NF?B binding to ST8SIA1 promoter. PLoS One (2013) 8(4):e62559. doi:10.1371/journal.pone.0062559
112. Rusnati M, Tanghetti E, Urbinati C, Tulipano G, Marchesini S, Ziche M, et al. Interaction of fibroblast growth factor-2 (FGF-2) with free gangliosides: biochemical characterization and biological consequences in endothelial cell cultures. Mol Biol Cell (1999) 10(2):313-27. doi:10.1091/mbc.10.2.313
113. Chang F, Li R, Ladisch S. Shedding of gangliosides by human medulloblastoma cells. Exp Cell Res (1997) 234(2):341-6. doi:10.1006/excr.1997.3619
114. Li RX, Ladisch S. Shedding of human neuroblastoma gangliosides. Biochim Biophys Acta (1991) 1083(1):57-64. doi:10.1016/0005-2760(91)90124-Z
115. Koochekpour S, Merzak A, Pilkington GJ. Vascular endothelial growth factor production is stimulated by gangliosides and TGF-ß isoforms in human glioma cells in vitro. Cancer Lett (1996) 102(1-2):209-15. doi:10.1016/0304-3835(96)04161-4
116. Malykh YN, Schauer R, Shaw L. N-glycolylneuraminic acid in human tumours. Biochimie (2001) 83(7):623-34. doi:10.1016/S0300-9084(01)01303-7
117. Chou H-H, Takematsu H, Diaz S, Iber J, Nickerson E, Wright KL, et al. A mutation in human CMP-sialic acid hydroxylase occurred after the Homo-Pan divergence. Proc Natl Acad Sci U S A (1998) 95(20):11751-6. doi:10.1073/pnas.95.20.11751
118. Irie A, Koyama S, Kozutsumi Y, Kawasaki T, Suzuki A. The molecular basis for the absence of N-glycolylneuraminic acid in humans. J Biol Chem (1998) 273(25):15866-71. doi:10.1074/jbc.273.25.15866
119. Hirabayashi Y, Kasakura H, Matsumoto M, Higashi H, Kato S, Kasai N, et al. Specific expression of unusual GM2 ganglioside with Hanganutziu-Deicher antigen activity on human colon cancers. Jpn J Cancer Res (1987) 78(3):251-60.
120. Kawachi S, Saida T. Analysis of the expression of Hanganutziu-Deicher (HD) antigen in human malignant melanoma. J Dermatol (1992) 19(11):827-30.
121. Bardor M, Nguyen DH, Diaz S, Varki A. Mechanism of uptake and incorporation of the non-human sialic acid N-glycolylneuraminic acid into human cells. J Biol Chem (2005) 280(6):4228-37. doi:10.1074/jbc.M412040200
122. Tangvoranuntakul P, Gagneux P, Diaz S, Bardor M, Varki N, Varki A, et al. Human uptake and incorporation of an immunogenic nonhuman dietary sialic acid. Proc Natl Acad Sci U S A (2003) 100(21):12045-50. doi:10.1073/pnas.2131556100
123. Yin J, Hashimoto A, Izawa M, Miyazaki K, Chen G-Y, Takematsu H, et al. Hypoxic culture induces expression of sialin, a sialic acid transporter, and cancer-associated gangliosides containing non-human sialic acid on human cancer cells. Cancer Res (2006) 66(6):2937-45. doi:10.1158/0008-5472.CAN-05-2615
124. Yin J, Miyazaki K, Shaner RL, Merrill AH Jr., Kannagi R. Altered sphingolipid metabolism induced by tumor hypoxia - new vistas in glycolipid tumor markers. FEBS Lett (2010) 584(9):1872-8. doi:10.1016/j.febslet.2009.11.019
125. Hayashi N, Chiba H, Kuronuma K, Go S, Hasegawa Y, Takahashi M, et al. Detection of N-glycolyated gangliosides in non-small-cell lung cancer using GMR8 monoclonal antibody. Cancer Sci (2013) 104(1):43-7. doi:10.1111/cas.12027
126. Casadesús AV, Fernández-Marrero Y, Clavell M, Gómez JA, Hernández T, Moreno E, et al. A shift from N-glycolyl- to N-acetyl-sialic acid in the GM3 ganglioside impairs tumor development in mouse lymphocytic leukemia cells. Glycoconj J (2013) 30(7):687-99. doi:10.1007/s10719-013-9473-y
127. Higashi H, Naiki M, Matuo S, Okouchi K. Antigen of "serum sickness" type of heterophile antibodies in human sera: identification as gangliosides with N-glycolylneuraminic acid. Biochem Biophys Res Commun (1977) 79(2):388-95. doi:10.1016/0006-291X(77)90169-3
128. Merrick JM, Zadarlik K, Milgrom F. Characterization of the Hanganutziu-Deicher (serum-sickness) antigen as gangliosides containing n-glycolylneuraminic acid. Int Arch Allergy Appl Immunol (1978) 57(5):477-80. doi:10.1159/000232140
129. Hanganutziu M. Hémagglutinines hétérogénétiques après injection de serum de cheval. C R Seances Soc Biol Fil (1924) 91:1457.
130. Deicher H. über die Erzeugung heterospezifischer Hämagglutinine durch Injektion artfremden Serums. Z Hyg Infektionskr (1926) 106:561. doi:10.1007/BF02176298
131. Kasukawa R, Kano K, Bloom ML, Milgrom F. Heterophile antibodies in pathologic human sera resembling antibodies stimulated by foreign species sera. Clin Exp Immunol (1976) 25(1):122-32.
132. Zhu A, Hurst R. Anti-N-glycolylneuraminic acid antibodies identified in healthy human serum. Xenotransplantation (2002) 9(6):376-81. doi:10.1034/j.1399-3089.2002.02138.x
133. Ravindranath MH, Yesowitch P, Sumobay C, Morton DL. Glycoimmunomics of human cancer: current concepts and future perspectives. Future Oncol (2007) 3(2):201-14. doi:10.2217/14796694.3.2.201
134. Cojocaru M, Silosi I. The significance of natural autoantibodies. Maedica (Buchar) (2009) 4(1):22-5.
135. Chapman CJ, Murray A, McElveen JE, Sahin U, Luxemburger U, Türeci ö, et al. Autoantibodies in lung cancer: possibilities for early detection and subsequent cure. Thorax (2008) 63(3):228-33. doi:10.1136/thx.2007.083592
136. Zhang J-Y, Casiano CA, Peng X-X, Koziol JA, Chan EKL, Tan EM. Enhancement of antibody detection in cancer using panel of recombinant tumor-associated antigens. Cancer Epidemiol Biomarkers Prev (2003) 12(2):136-43.
137. Storr SJ, Chakrabarti J, Barnes A, Murray A, Chapman CJ, Robertson JF. Use of autoantibodies in breast cancer screening and diagnosis. Expert Rev Anticancer Ther (2006) 6(8):1215-23. doi:10.1586/14737140.6.8.1215
138. Rodrígues-Zhurbenko N, Martínes D, Blanco R, Rondón T, Griñán T, Hernández AM. Human antibodies reactive to NeuGcGM3 ganglioside have cytotoxic antitumor properties. Eur J Immunol (2013) 43:826-37. doi:10.1002/eji.201242693
139. Couzin-Frankel J. Breakthrough of the year 2013. Cancer immunotherapy. Science (2013) 342(6165):1432-3. doi:10.1126/science.342.6165.1432
140. Schuster M, Nechansky A, Loibner H, Kircheis R. Cancer immunotherapy. Biotechnol J (2006) 1(2):138-47. doi:10.1002/biot.200500044
141. Cheever MA, Allison JP, Ferris AS, Finn OJ, Hastings BM, Hecht TT, et al. The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research. Clin Cancer Res (2009) 15(17):5323-37. doi:10.1158/1078-0432.CCR-09-0737
142. Modak S, Cheung NK. Disialoganglioside directed immunotherapy of neuroblastoma. Cancer Invest (2007) 25(1):67-77. doi:10.1080/07357900601130763
143. Krengel U, Olsson L-L, Martínez C, Talavera A, Rojas G, Mier E, et al. Structure and molecular interactions of a unique antitumor antibody specific for N-glycolyl GM3. J Biol Chem (2004) 279(7):5597-603. doi:10.1074/jbc.M311693200
144. Talavera A, Eriksson A, Ökvist M, López-Requena A, Fernández-Marrero Y, Pérez R, et al. Crystal structure of an anti-ganglioside antibody, and modelling of the functional mimicry of its NeuGc-GM3 antigen by an anti-idiotypic antibody. Mol Immunol (2009) 46(16):3466-75. doi:10.1016/j.molimm.2009.07.032
145. Agostino M, Yuriev E, Ramsland PA. Antibody recognition of cancer-related gangliosides and their mimics investigated using in silico site mapping. PLoS One (2012) 7(4):e35457. doi:10.1371/journal.pone.0035457
146. Rojas G, Pupo A, Gómez S, Krengel U, Moreno E. Engineering the binding site of an antibody against N-Glycolyl GM3: from functional mapping to novel anti-ganglioside specificities. ACS Chem Biol (2013) 8(2):376-86. doi:10.1021/cb3003754
147. Gajdosik Z. Racotumomab - a novel anti-idiotype monoclonal antibody vaccine for the treatment of cancer. Drugs Today (Barc) (2014) 4:301-7. doi:10.1358/dot.2014.50.4.2116670
148. Osorio M, Gracia E, Reigosa E, Hernandez J, de la Torre A, Saurez G, et al. Effect of vaccination with N-glycolyl GM3/VSSP vaccine by subcutaneous injection in patients with advanced cutaneous melanoma. Cancer Manag Res (2012) 4:341-5. doi:10.2147/CMAR.S226174
149. Alfonso S, Valdés-Zayas A, Santiesteban ER, Flores YI, Areces F, Hernández M, et al. A randomized, multicenter, placebo-controlled clinical trial of racotumomab-alum vaccine as switch maintenance therapy in advanced non-small-cell-lung cancer patients. Clin Cancer Res (2014) 20(14):1-12. doi:10.1158/1078-0432.CCR-13-1674
150. Eggermont AM, Suciu S, Ruka W, Marsden J, Testori A, Corrie P, et al. Post-operative adjuvant ganglioside GM2-KLH21 vaccination treatment vs observation in stage II (T3-T4N0M0) melanoma: 2nd interim analysis led to an early disclosure of the results. J Clin Oncol (2008) 26.
151. Eggermont AM, Suciu S, Rutkowski P, Marsden J, Santinami M, Corrie P, et al. Adjuvant ganglioside GM2-KLH/QS-21 vaccination versus observation after resection of primary tumor 1.5 mm in patients with stage II melanoma: results of the EORTC 18961 randomized phase III trial. J Clin Oncol (2013) 31:3831-7. doi:10.1200/JCO.2012.47.9303
152. Herrera ZM, Ramos TC. Pilot study of a novel combination of two therapeutic vaccines in advanced non-small-cell lung cancer patients. Cancer Immunol Immunother (2014) 63(7):737-47. doi:10.1007/s00262-014-1552-9
153. Tessier MB, DeMarco ML, Yongye AB, Woods RJ. Extension of the GLYCAM06 biomolecular force field to lipids, lipid bilayers and glycolipids. Mol Simul (2008) 34(4):349-63. doi:10.1080/08927020701710890
154. Czogalla A, Grzybek M, Jones W, Coskun ü. Validity and applicability of membrane model systems for studying interactions of peripheral membrane proteins with lipids. Biochim Biophys Acta (2014) 1841(8):1049-59. doi:10.1016/j.bbalip.2013.12.012